{"schema_version":"secwatch.filing_event.v1","accession":"0001933414-25-000120","form_type":"8-K","ticker":"MLYS","cik":"0001933414","company_name":"Mineralys Therapeutics, Inc.","filed_at":"2025-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.637689+00:00","generated_at":"2026-05-17T08:39:28.824650+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Mineralys prices upsized $250M public offering at $25.50/share","bullets":["9,803,921 shares at $25.50/share; total gross proceeds ~$250M.","Net proceeds ~$234.7M (~$269.9M if underwriters' option exercised).","Proceeds to fund lorundrostat clinical development, R&D, manufacturing, and pre-commercialization.","Underwriters: BofA, Evercore, Goldman, Stifel, Wells Fargo; closing expected Sept 4, 2025.","Upsized offering reflects strong demand; underwriters have 30-day option for 1.47M additional shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001933414-25-000120","json":"https://secwatch.observer/filing/0001933414-25-000120.json","markdown":"https://secwatch.observer/filing/0001933414-25-000120.md","text":"https://secwatch.observer/filing/0001933414-25-000120.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933414/000193341425000120/0001933414-25-000120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933414/000193341425000120/mlys-20250902.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:39:28.824650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}